ADXS11-001 immunotherapy targeting HPV-E7: Updated survival and
safety data from a
Phase 2 study in Indian women with recurrent cervical cancer
Robert Petit1 and Partha Basu21Advaxis, Inc. Princeton, NJ
2Chittaranjan National Cancer Institute, Kolkata, India
Abstract
Life Cycle of Lm in APC
Lm-LLO Immunotherapy Safety: Frequency of SAEs in 110 patient
Phase 2: ADXS11-001 vs. Chemotherapy
Overall Survival
Lm-LLO-E7-15 Best Response Data
ConclusionsCase Study: Patient 110-002
Landmark Survival Duration of Response (PFS)
Overall Survival: Aggressive vs. Non-
Aggressive Disease
Response by Aggressiveness of Disease &
Treatment Group
Lm-LLO-E7-015: A Randomized Phase 2 Study to Assess the Safety
& Efficacy of
ADXS-HPV +/- cisplatin Treatment for Recurrent Cervical
Cancer
Trial Design: Lm-LLO-E7-15
Safety
